Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.66 - $5.34 $34,770 - $50,730
-9,500 Reduced 9.5%
90,500 $364,000
Q1 2024

May 15, 2024

BUY
$4.19 - $5.59 $419,000 - $559,000
100,000 New
100,000 $498,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $310M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Awm Investment Company, Inc. Portfolio

Follow Awm Investment Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Awm Investment Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Awm Investment Company, Inc. with notifications on news.